← Back to All Filings

Spruce Biosciences Director in Stock Option Repricing Transaction

Low SignificanceDecember 15, 2025 at 7:02:17 PM EST

SPRUCE BIOSCIENCES, INC.

$SPRB4CIK: 0001683553

Subscribe to track SPRB

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Spruce Biosciences Director in Stock Option Repricing

Company: SPRUCE BIOSCIENCES, INC. (SPRB) Form: 4 | Filed: 2025/12/15 Significance: Low

Insider: Barretto-Ko Percival Title: Director

Transaction: • Type: Option Repricing • Shares: 800 options exchanged • Value: $0.00 • Owned After: 800 options

Key Insight: This is a non-cash administrative action. An old option for 800 shares with an exercise price of $169.50 was cancelled and replaced with a new option for 800 shares with a lower exercise price of $104.13. This is not an open market buy or sell.

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: SPRUCE BIOSCIENCES, INC. (SPRB)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: A director participated in a company-wide stock option repricing, exchanging 800 old options for 800 new ones with a lower exercise price of $104.13.
  • Market Impact: Neutral. This is a non-cash, administrative transaction with no immediate market impact or change in insider capital at risk.

Company Information

FieldValue
CompanySPRUCE BIOSCIENCES, INC.
Ticker SymbolSPRB
CIK0001683553
IndustryPHARMACEUTICAL PREPARATIONS

Insider Information

FieldValue
NameBarretto-Ko Percival
CIK0001978654
Title/Positionnull
RelationshipDirector

Transaction Details

FieldValue
Form Type4
Transaction Date2025-12-11
Transaction CodeA / D
Security TypeStock Option (Right to Buy)
Shares Involved800 (Exchanged)
Price Per Share$0.00
Total Value$0.00
Shares Owned After800 (Options)
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$0
% of Market Cap0.0%
Shares Transacted800 (Options)
% of Shares OutstandingNot available
Post-Transaction Ownership800 options
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: The transaction has no monetary value and therefore has a 0% impact on the company's $0.11 billion market capitalization.
  • Ownership Concentration: The transaction does not change the number of underlying shares the insider has a right to acquire; it only adjusts the exercise price. It does not affect ownership concentration.
  • Transaction Significance: The transaction is a stock option repricing, a common practice for companies whose stock price has declined, intended to re-incentivize employees and directors. It is an administrative change with no capital outlay from the insider and is considered low significance.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: This is a non-cash, non-market transaction that exchanges one derivative security for another. It does not signal new insider sentiment or involve any capital investment.

Volume & Sentiment

  • Expected Volume Impact: None. The transaction occurred off-market.
  • Sentiment Indicator: Neutral. While option repricings can be viewed negatively by some investors as they re-price incentives after poor stock performance, this single, small transaction is unlikely to influence market sentiment.

Additional Context

Transaction Notes

  • Special Circumstances: The filing explicitly states this was part of a "one-time stock option repricing" program. The old option with an exercise price of $169.50 was disposed of (Code D) and a new option with an exercise price of $104.13 was acquired (Code A). The number of shares and vesting schedule remained unchanged.
Topics:#SECFiling#Form4#SPRB#SpruceBiosciences#InsiderTrading#StockOptions#CorporateGovernance#Biotech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.